PATENT CLAIM ANALYSIS

Application Number: 16123072
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-01
Patent Classification: ["544", "310000"]

Abstract:
The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), and Parkinson's disease.

Claim (Index 3):
The method of  claim 2  wherein the compound or a pharmaceutically acceptable salt thereof is a compound of Formula IB-1, IB-2, IB-3, IB-4, IB-5, IB-6, IB-7, IB-8, IB-9, or IB-10: or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 97.0
- Lexical Diversity: 1.68519
- Patent Class: 544.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14311963', '15729111', '15349075', '14819541', '14339123']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8033595362064305
- 35 USC 102 Novelty (BERT): 0.5860461995499281
- Combined Prediction Score: 0.7816282025407802
- Mean Citation Score: 447.258236
- Max Citation Score: 471.30627
- Similarity Product: 468.7093572870916

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test